Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for ABVC BioPharma, Inc. (ABVC : NSDQ)

• Company Description    ABCV BIOPHARMA identifies & commercializes drugs & medical devices developed. ABCV BIOPHARMA, formerly known as AMER BRIVISION, is based in FREMONT, CA. Number of Employees: 30

• Price / Volume Information    Yesterday's Closing Price: $2.12 Daily Weekly Monthly 20 Day Moving Average: 43,245 shares Shares Outstanding: 30.31 (millions) Market Capitalization: $64.25 (millions) Beta: 0.72 52 Week High: $6.03 52 Week Low: $1.95 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -17.19% -9.26% 12 Week -16.21% -9.08% Year To Date -37.46% -25.63%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 44370 Old Warm Springs Blvd - Fremont,CA 94538 USA ph: 510-668-0881 fax: - None http://www.ambrivis.com

• General Corporate Information    Officers Howard Doong - Chief Executive Officer Eugene Jiang - Chairman of the Board of Directors Chihliang An - Chief Financial Officer Yen-Hsin Chou - Director Shin-Yu Miao - Director Peer Information ABVC BioPharma, Inc. (CORR.) ABVC BioPharma, Inc. (RSPI) ABVC BioPharma, Inc. (CGXP) ABVC BioPharma, Inc. (BGEN) ABVC BioPharma, Inc. (GTBP) ABVC BioPharma, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 00091F106 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/11/22 Share - Related Items Shares Outstanding: 30.31 Most Recent Split Date: 5.00 (0.06:1) Beta: 0.72 Market Capitalization: $64.25 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 6.84 Price/Cash Flow: - Price / Sales: 141.32 EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: 35.48% Sales Growth vs. Year Ago Period: -90.11% vs. Previous Quarter: -% ROE 03/31/22 - -308.85 12/31/21 - -271.09 09/30/21 - -318.25 ROA 03/31/22 - -149.81 12/31/21 - -111.39 09/30/21 - -91.57 Current Ratio 03/31/22 - - 12/31/21 - 2.61 09/30/21 - 2.07 Quick Ratio 03/31/22 - - 12/31/21 - 2.60 09/30/21 - 2.05 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - -2,186.90 Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - -2,145.77 Pre-Tax Margin 03/31/22 - - 12/31/21 - -3,149.16 09/30/21 - -2,282.14 Book Value 03/31/22 - - 12/31/21 - 0.31 09/30/21 - 0.28 Inventory Turnover 03/31/22 - - 12/31/21 - 0.24 09/30/21 - 0.28 Debt-to-Equity 03/31/22 - - 12/31/21 - 0.00 09/30/21 - 0.01 Debt-to-Capital 03/31/22 - - 12/31/21 - 0.00 09/30/21 - 1.35

Powered by Zacks Investment Research ©